▶ Focus on specialized startups acceleration in the field of biotechnologies and stem cells
▶ Substantive distinction and difference with accelerators in service and IT
▶ Analysis of real needs of industry, government and market
▶ Analysis of imported biomedicines as priorities of admitting technology teams
▶ Supply of infrastructure required by admitted technology startups, Training & Mentorship
▶ Solicit investor and guarantee investment for technologies made by technology teams
▶ Adoption of diverse models of partnership for different beneficiaries such as technology teams, investors, production companies, companies that need services and …
Technology startups usually need specialized laboratory and infrastructure equipment to work on their idea.
In most cases, market is not available for technology startups and serious measures need to be taken for access to market.
Technology startups are less attractive for non-specialized investors due to difficult and time-consuming access to technology as compared to service startups.
The common acceleration pattern such as funding event, Seed Money, receiving stock and … are not necessarily suitable for technology accelerator.
Launching stem cells accelerator of PersisGen in Kharazmi University with a focus on stem cells technologies
Defining technology accelerator for the audience out of biotechnology industry; raising awareness about nature of accelerator for audience in the pharmaceuticals and biotechnology industry
Developing PersisGen business model and launching PersisGen branch offices in Shiraz, Tabriz and Urmia in order to reconnoiter experts from various parts of Iran in the biopharmaceuticals field.
A few countries have ventured production of biological medicines due to patent issues and its knowledge/capital intensive nature.
Biological medicines are basically produced for special and refractory diseases such as cancer and autoimmune disease.
It has a long term of output and requires a high investment volume.
Manufacturing biological medicines is a highly technical complicated process.
Country’s pharmaceutical security in the field of biological medicines is of high importance (in terms of cost and access).
Biological medicines must be administered by injection and stored refrigerated.
Clinical trial period is minimum 1.5 to 2 years and course of production is at least 5 years for biological medicines.
Manufacturing biological medicines is featured by high rate of educated people employment.
The technology team supplies consumables in addition to knowledge and manpower.
Not receiving stock from technology teams to protect freedom of operation, and at the same time, non provision of seed money.
Infrastructural facilities, including physical space, lab, human resource, mentorship, technical training and general business training, and the last but not least, commitment to sell resulted technology
Conducting training courses on business establishment and governance as well as administrative support including company’s registration, obtaining commercial card, assisting access to knowledge-based certificate and … through companies providing commercialization services.
The venue for receiving loan and/or concluding VC agreement with a preferable interest rate through biotechnology development headquarters
The pre-acceleration period is 2-4 months and the acceleration period is 15-20 months for technology teams
Not receiving stock of technology companies during acceleration period of income generation from providing technical services and soliciting outsourced projects
Adoption of diverse models of partnership for different beneficiaries such as technology teams, investors, production companies, companies that need services and …
Focus on specialized startups acceleration in the field of biotechnologies and stem cells and substantive distinction and difference with accelerators in service and IT domains
Supply of infrastructure required by admitted technology startups and solicit investor and guarantee investment for technologies made by technology teams
Analysis of real needs of industry, government and market and analysis of imported biomedicines as priorities of admitting technology teams
Recruiting young educated manpower and creating job opportunities based on merits according to annual evaluations
Entering international markets through export and transfer of know-how based on standards of destination countries 2 years after product is introduced to the domestic market
Maximum market share locally based on clinical trials and scientific/ theoretical methods; so as to the market share will be 20% in the initial year, increasing up to 70% within 3 years time.
High quality and safety of products, taking advantage of the modern manufacturing process of biotechnological medicines based on the latest world standards
Manufacturing biological medicines based on recombinant proteins and monoclonal antibodies, totally unprecedented in the country
Creation, presentation and implementation of new ideas in the context of improving organizational performance
Transparency and good will towards others and building trust through conformity of thoughts, words and deeds
Recognizing and taking into serious account of rights of others and honoring human dignity
Being accountable for decisions made and entrusted duties together with loyalty and compassion
No. 125, 22nd km of Tehran-Karaj Makhsous road, Tehran, Iran.
+98 (21) 46074876
+98 (21) 46074876
PersisGen Par welcomes any suggestion and/or criticism for improvement of facilities and better quality of provided services; so please send us your comments through the available form.
We’ll Contact you as soon as possible.